Japan Acute Myeloid Leukaemia Market Insight
Published: 28 May 2026 | Report Format: Electronic (PDF)
The Japan acute myeloid leukaemia (AML) market is expected to experience steady growth 7.8% owing to a rapidly ageing population, increasing adoption of targeted therapy and precision oncology approaches, growing investment in haematological oncology research, and expanding access to next-generation treatment regimens including FLT3 inhibitors, BCL-2 inhibitors, and hypomethylating agents.
Japan Acute Myeloid Leukaemia Market Insights Forecasts to 2035
- The Japan Acute Myeloid Leukaemia Market Size Was Estimated USD 142.6 Million in 2025
- The Market Size is Expected to Grow at a CAGR of around 7.8% from 2025 to 2035
- The Japan Acute Myeloid Leukaemia Market Size is Expected to rise around USD 302.4 Million by 2035
Notable Insights for the Japan Acute Myeloid Leukaemia Market
- The treatment-based segmentation indicates that the Targeted Therapy and Chemotherapy segment holds a commanding position with almost 54% market share in the Japan Acute Myeloid Leukaemia Market in 2025, driven by wide adoption of FLT3 inhibitors such as gilteritinib and venetoclax-based combination regimens in hospital oncology Centres.
- The end-user segmentation shows that the Hospital and Speciality Oncology Clinics segment dominates with a market share of almost 61% in the Japan Acute Myeloid Leukaemia Market in 2025, supported by the strong infrastructure of haematology departments, growing bone marrow transplant programmes, and increasing access to approved novel agents.
- The global revenue for Astellas Pharma Inc. in fiscal year 2025 was estimated at approximately $11.4 billion, supported in part by its FLT3 inhibitor Xospata (gilteritinib), which is a key approved therapy for relapsed or refractory AML in Japan and internationally.
- As per expectations, rising integration of next-generation sequencing (NGS) diagnostics, AI-driven treatment decision support tools, and growing clinical trial activity will drive market expansion, with molecular-targeted approaches improving remission rates by up to 38% and reducing time to treatment response by up to 26% in mutation-specific AML patient groups.
Download the eBook (ToC)
Research Methodologies Used to Analyze the Japan Acute Myeloid Leukaemia Market
The Japan acute myeloid leukaemia market is analyzed through a blend of primary and secondary research approaches to ensure accurate and reliable market intelligence. Primary research is conducted through consultations with haematology specialists, oncology drug manufacturers and distributors, hospital procurement teams, regulatory experts, and cancer research institutions to assess treatment trends, pipeline developments, and competitive activities. Secondary research involves reviewing published clinical studies, company annual reports, government health policy documents, PMDA regulatory filings, industry databases, and global oncology journals related to haematological malignancies. Market estimation, epidemiological analysis, and forecast modelling methodologies are applied to evaluate market size, growth opportunities, pricing dynamics, and investment patterns across treatment segments.
Decisions Advisors Research Methodology: Trusted Insights for Strategic Decision-Making
What is Decisions Advisors Research?
Decisions Advisors research delivers comprehensive market intelligence through detailed industry analysis, competitive benchmarking, trend forecasting, and data-driven business insights. Our research methodology combines advanced analytical frameworks with extensive primary and secondary research to help organizations make informed and strategic business decisions.
Competitive Analysis:
The report offers an in-depth analysis of the key organizations and companies active in the Japan Acute Myeloid Leukaemia Market, along with a comparative evaluation based on their product portfolios, business overviews, geographic presence, corporate strategies, segment market share, and SWOT analysis. The report also provides detailed coverage of recent company developments including new drug approvals, clinical trial advancements, strategic partnerships, licensing agreements, mergers and acquisitions, and collaborative research alliances. This enables a thorough assessment of the overall competitive landscape within the market.
Top Companies in Japan Acute Myeloid Leukaemia Market
- Astellas Pharma Inc.
- Daiichi Sankyo Co., Ltd.
- AbbVie Inc.
- Bristol-Myers Squibb Company
- Novartis AG
- Pfizer Inc.
- Otsuka Pharmaceutical Co., Ltd.
- Jazz Pharmaceuticals plc
- Agios Pharmaceuticals Inc.
- Rigel Pharmaceuticals Inc.
Recent Developments:
- In February 2026, Astellas Pharma Inc. announced an expanded clinical collaboration with a Japanese national cancer research consortium to investigate next-generation FLT3 inhibitor combination regimens for newly diagnosed and relapsed AML patients, strengthening its position in the domestic haematological oncology segment.
- In September 2025, AbbVie Inc. expanded the commercial availability of its BCL-2 inhibitor venetoclax (Venclexta) in combination with azacitidine for elderly and treatment-ineligible AML patients across major oncology centres in Japan, following positive real-world outcomes data from post-marketing surveillance programmes.
Market Segmentation:
Japan Acute Myeloid Leukaemia Market, By Treatment Type
- Chemotherapy (Cytarabine-based Regimens, Anthracyclines)
- Targeted Therapy (FLT3 Inhibitors, BCL-2 Inhibitors, IDH Inhibitors)
- Stem Cell Transplantation
- Hypomethylating Agents
- Immunotherapy and Antibody-Drug Conjugates
Japan Acute Myeloid Leukaemia Market, By Diagnostic Approach
- Next-Generation Sequencing (NGS) Based Molecular Diagnostics
- Flow Cytometry and Immunophenotyping
- Cytogenetic and Karyotype Analysis
- Bone Marrow Biopsy and Morphological Assessment
- AI-Assisted Treatment Decision Support Systems
Japan Acute Myeloid Leukaemia Market, By End User
- Hospitals and Haematology Departments
- Speciality Oncology Clinics
- Academic and Research Institutes
- Ambulatory Care and Day Infusion Centres
- Diagnostic Laboratories
Expert Views:
The growth of the acute myeloid leukaemia market in Japan will be shaped by a combination of demographic pressure from one of the world's most aged populations, continued advances in precision oncology, and a strengthening pipeline of mutation-targeted therapies. The increasing integration of molecular diagnostics, particularly NGS-based testing to identify FLT3, IDH1/2, and NPM1 mutations, is enabling more individualised treatment planning and driving uptake of targeted agents. The expansion of AI-assisted clinical decision tools and real-world data programmes will further improve treatment outcomes and efficiency across hospital and speciality oncology settings. Growing collaboration between Japanese pharmaceutical companies and global biopharmaceutical firms, along with supportive PMDA regulatory frameworks including the Sakigake designation pathway, is expected to accelerate the approval and commercialisation of novel AML therapies in Japan through 2035.